Medimmune Limited

Humabs Biomed Sa

Vir Biotechnology, Inc.

Elisabetta Cameroni

Davide Corti

Martina Beltramello

Charles K Stover

Xiaodong Xiao

Qun Wang

Meghan Pennini

Gilad Kaplan

Gyorgy Pal Snell

Anna DeMarco

Chew-shun Chang

Florian A Lempp

Jamese Johnson Hilliard

Katja Fink

Dora Pinto

Amalio Telenti

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO1 and induce opsonophagocytic killing of(e.g.,). The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O1 antibodies and uses thereof

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.

Antibodies against SARS-CoV-2 and methods of using the same

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO2 and induce opsonophagocytic killing of(e.g.,) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Growing community of inventors

Bellinzona, Switzerland

Elisabetta Cameroni